July 22, 2021
CPC to Manage Planning, Organization, and Day-to-Day Execution of the Trial LAS VEGAS, July 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has selected CPC Clinical Research (CPC), a full-service academic research organization... READ MORE
June 23, 2021
Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today... READ MORE
June 22, 2021
Global Contract Research Organization (CRO) Avania to Manage All Regulatory Affairs in Connection with JanOne's Phase 2b Trial Preparedness and Execution LAS VEGAS, June 22, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced its selection of... READ MORE
June 15, 2021
World leader in addiction science joins team of experts in diseases and disorders that cause chronic pain LAS VEGAS, June 15, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the appointment of Nicholas E. Goeders, Ph.D.... READ MORE
JanOne Engages DC Consulting LLC for Government and Private Sector Initiatives
June 10, 2021
LAS VEGAS, June 10, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that it has engaged the services of DC Consulting LLC, a strategy and management consulting firm specializing in government affairs, regulatory guidance, marketing strategy,... READ MORE
JanOne Announces Definitive Agreement to Sell its Legacy Recycling Business for $25 Million
February 25, 2021
Successful disposition will facilitate continued strategic focus on high-value late-stage biopharma asset JAN101 for the treatment of peripheral artery disease (PAD) LAS VEGAS, Feb. 25, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced that is has... READ MORE
JanOne Announces Closing of $6.0 Million Common Stock Offering
February 2, 2021
Net proceeds will help support planning of clinical trials for JAN101, the company’s lead drug candidate LAS VEGAS, February XX, 2021 /PRNewswire/ -- JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced the closing of previously announced its securities offering... READ MORE
JanOne Prices $6.0 Million Common Stock Offering
January 29, 2021
Las Vegas, NV, January 29, 2021 (GLOBE NEWSWIRE) -- JanOne Inc. (NASDAQ: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, today announced it has entered into a securities purchase agreement with institutional investors for the purchase and sale of 571,428 shares of its common... READ MORE
Dr. Giordano’s interview with eHealth Radio Network
December 15, 2020
Our CSO, Dr. Giordano, sat down with @EricDye to discuss JanOne, treating the #opioid industry, bringing to market drugs with non-addictive pain-relieving properties, and more. $JAN #Healthcare #Medical Listen to the full interview here via @eHealthRadio https://ehealthradio.podbean.com/e/janone-treating-the-opioid-industry-and-bringing-to-market-drugs-with-non-addictive-pain-relieving-properties READ MORE